The Glenn E. Adriance Sells 8,070 Shares of Mesa Laboratories, Inc. (MLAB) Stock, Report finds

The Glenn E. Adriance Sells 8,070 Shares of Mesa Laboratories, Inc. (MLAB) Stock, Report finds

Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) opened at 121.30 on Thursday. The stock has a 50 day moving average price of $121.91 and a 200-day moving average price of $119.14. The stock has a market capitalization of $447.23 million, a PE ratio of 40.11 and a beta of 0.61. Mesa Laboratories, Inc. has a 52-week low of $79.79 and a 52-week high of $137.20.

Mesa Laboratories, Inc. (NASDAQ:MLAB) insider Glenn E. Adriance sold 8,070 shares of the business’s stock in a transaction that occurred on Tuesday, February 7th. The shares were sold at an average price of $124.15, for a total value of $1,001,890.50. Following the completion of the transaction, the insider now directly owns 15,170 shares of the company’s stock, valued at $1,883,355.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings results on Thursday, February 2nd. The company reported $0.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.23. Mesa Laboratories had a return on equity of 18.52% and a net margin of 12.24%. On average, equities research analysts anticipate that Mesa Laboratories, Inc. will post $2.97 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 15th. Investors of record on Tuesday, February 28th will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, February 24th. This represents a $0.64 dividend on an annualized basis and a yield of 0.53%. Mesa Laboratories’s dividend payout ratio is presently 21.12%.

A number of analysts have recently commented on MLAB shares. Janney Montgomery Scott restated a “buy” rating on shares of Mesa Laboratories in a research report on Friday, December 23rd. Zacks Investment Research upgraded Mesa Laboratories from a “strong sell” rating to a “hold” rating in a research report on Wednesday, January 11th.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Related posts

Leave a Comment